BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
With the expansion, the hospital’s total bed capacity will rise from 380 to 539 beds
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
Panacea Biotec receives LoA from CMSS
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
